NCT03253913View on ClinicalTrials.gov

Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 31, 2018

Primary Completion Date

October 15, 2022

Study Completion Date

October 15, 2022

Conditions
Lymphangioleiomyomatosis
Interventions
DRUG

Sirolimus

Patients will have been on a stable dose of sirolimus prior to enrolling and will continue that throughout the study.

DRUG

Resveratrol

Escalating doses of resveratrol will be given throughout the study. Patients will start at 250mg daily for 8 weeks, followed by 500mg daily for 8 weeks, and 500mg BID for the last 8 weeks.

Trial Locations (1)

45267

University of Cincinnati, Cincinnati

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

University of Cincinnati

OTHER

NCT03253913 - Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial | Biotech Hunter | Biotech Hunter